| 沉默Bcl-XL逆转人胶质瘤获得性SLC22A18的耐药 |
| |
| 引用本文： | 杨 标,楚胜华,马延斌. 沉默Bcl-XL逆转人胶质瘤获得性SLC22A18的耐药[J]. 现代肿瘤医学, 2018, 0(7): 981-984. DOI: 10.3969/j.issn.1672-4992.2018.07.001 |
| |
| 作者姓名： | 杨 标 楚胜华 马延斌 |
| |
| 作者单位： | 上海交通大学医学院附属第九人民医院神经外科，上海 201999 |
| |
| 基金项目： | 教育部留学回国人员科研启动基金项目(编号:082003)；上海市卫生和计划生育委员会科研基金面上项目(编号:201540266)；上海交通大学医工交叉研究基金项目(编号:YG2015MS25)；上海交通大学医学院附属第三人民医院自然科学研究基金项目(编号:syz2015-015) |
| |
| 摘 要： | 目的:探讨RNA干扰Bcl-XL(siRNA）在人胶质瘤获得性SLC22A18的耐药中的作用。方法:以Bcl-XL siRNA转染获得性SLC22A18耐药的人胶质瘤U251-SLC22A18/R细胞，用重组人SLC22A18蛋白处理，MTT法和流式细胞仪检测肿瘤细胞的存活率，免疫印迹法检测凋亡相关蛋白Caspase-3和Caspase-8的表达情况。结果:Bcl-XL siRNA能够降低U251-SLC22A18/R细胞中Bcl-XL的表达，也能逆转其对SLC22A18的耐药。U251-SLC22A18/R细胞经过Bcl-XL siRNA和重组人SLC22A18蛋白共同处理4 h后细胞凋亡率>50%，细胞存活率<30%；而对照组和重组人SLC22A18蛋白处理组的细胞凋亡率和存活率无明显变化。经Bcl-XL siRNA与重组人SLC22A18蛋白联合处理后，U251-SLC22A18/R细胞中Caspase-3和Caspase-8均明显活化。结论:Bcl-XL siRNA能有效逆转人胶质瘤获得性SLC22A18的耐药，为治疗胶质瘤耐药提供一种新的思路。
|
| 关 键 词： | 胶质瘤 SLC22A18 耐药 Bcl-XL RNA干扰 |
Overcoming acquired resistance by SLC22A18 silencing in human glioma |
| |
| Yang Biao,Chu Shenghua,Ma Yanbin. Overcoming acquired resistance by SLC22A18 silencing in human glioma[J]. Journal of Modern Oncology, 2018, 0(7): 981-984. DOI: 10.3969/j.issn.1672-4992.2018.07.001 |
| |
| Authors: | Yang Biao Chu Shenghua Ma Yanbin |
| |
| Affiliation: | Department of Neurosurgery，Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine，Shanghai 201999，China. |
| |
| Abstract: | Objective:To study the reversing effect of Bcl-XL small interfering RNA (siRNA) on the acquired resistance to SLC22A18 in human glioma.Methods:Human glioma U251-SLC22A18/R cells，with acquired resistance to SLC22A18，were transfected with Bcl-XL siRNA followed by the treatment of SLC22A18 protein.The survival rate of U251-SLC22A18/R cells was respectively analyzed by MTT and FACS methods，and activation of apoptotic signaling proteins Caspase-3 and Caspase-8 was assessed by Western blotting analysis.Results:Bcl-XL siRNA could effectively decrease the protein expression of Bcl-XL and reversed the acquired resistance to SLC22A18 in U251-SLC22A18/R cells.After the combination treatment of Bcl-XL siRNA and SLC22A18 protein for 4 h，the cell apoptotic rate was more than 50% and the survival rate was less than 30%.There was no effect on the survival rate after the control treatment or SLC22A18 protein treatment alone.Caspase-3 and Caspase-8 were significantly activated after the the combination treatment with Bcl-XL siRNA and SLC22A18 protein.Conclusion:Bcl-XL siRNA can reverse the acquired resistance to SLC22A18 in human glioma，it might be a novel strategy for overcoming the resistance in glioma therapy. |
| |
| Keywords: | glioma SLC22A18 resistance Bcl-XL RNA interference |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
